GlassScriptPhysician profile
Jeena Sandeep
NPI 1407034242
$1,482.53
in general payments reported to CMS, 2019-2025
24 companies · $492 in 2025
The $492 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $13.05 · 2021: $17.35 · 2022: $81.03 · 2023: $244 · 2024: $525 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,261.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $291.44 | 2019-2025 | Evenity, Prolia, Prolia |
| Lilly USA, LLC | $214.40 | 2019-2025 | Jardiance, Mounjaro |
| Novo Nordisk INC | $140.09 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $123.36 | 2024-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.38 | 2022-2025 | Jardiance |
| Abbvie INC. | $91.94 | 2019-2024 | |
| Corcept Therapeutics | $67.05 | 2025 | Korlym |
| Medtronic, INC. | $53.85 | 2023-2024 | Minimed 780g |
| Abbott Laboratories | $50.89 | 2023-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $44.89 | 2024-2025 | |
| Mannkind Corporation | $38.41 | 2023-2025 | Afrezza |
| Tolmar, INC. | $32.86 | 2023 | |
| Ascendis Pharma Endocrinology INC | $27.52 | 2025 | Yorvipath |
| Kyowa Kirin, INC. | $25.40 | 2024 | Crysvita |
| Alvogen INC | $24.84 | 2025 | Teriparatide |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sandoz INC. | $23.81 | 2025 | Jubbonti |
| Dexcom, INC. | $22.33 | 2023 | Dexcom G6 Transmitter |
| Sequel Med Tech, LLC | $20.29 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $19.90 | 2025 | |
| Insulet Corporation | $17.89 | 2024 | Omnipod |
| Horizon Therapeutics Plc | $15.96 | 2023 | Tepezza |
| Beta Bionics, INC. | $13.28 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Medtronic Minimed, INC. | $13.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $12.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeena Sandeep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.